Olivier Marcq
Executive Director Gilead Sciences
Olivier is an expert in bioconjugation therapeutics with more than 20 years of leadership expertise in the pharmaceutical industry encompassing CMC operation and strategy, GMP manufacturing as well as R&D, early and late phase development of biologics, particularly ADCs and conjugate vaccines. Olivier joins Gilead Science via the acquisition of Tubulis GmbH (Munich, DE) where he was SVP CMC and Clinical Supply. He joined Tubulis in April 2022 after holding positions at Vaxcyte (San Carlos, CA). There he led programs and well as process development and manufacturing activities for multivalent bioconjugate vaccines (VAX-24, VAX-31, VAX-A1). His prior experiences also comprise positions at Astellas Pharma (Agensys) where he had a chance to contribute to Padcev® development, Pfizer and Wyeth, where he led team and projects for the development and manufacturing of ADCs and other bioconjugate therapeutics (Prevnar13, Prevnar20 / PCV20®). Olivier obtained his PhD in Chemistry at the Université de Bourgogne, France and an Engineering degree from INSA Rouen, France.
Seminars
- Compare clinical and commercial ADC manufacturing processes alongside emerging conjugation technologies to assess process and supply-chain complexity
- Exploring opportunities for continuous manufacturing, including barriers to industry adoption
- Reviewing insights on the performance, scalability, and stability of ADCs across multiple clinical programmes